90 related articles for article (PubMed ID: 412904)
1. Study of platelet aggregation in vivo: IV Effect of pyrimido-pyrimidine derivatives.
Ambrus JL; Ambrus CM; Gastpar H; Thurber L; Miller R; Fretwell B; Lane KP
J Med; 1977; 8(5):287-94. PubMed ID: 412904
[TBL] [Abstract][Full Text] [Related]
2. Studies on platelet aggregation in vivo. VI. Effect of a pyrimido-pyrimidine derivative [RA233] on tumor cell metastasis.
Ambrus JL; Ambrus CM; Gastpar H
J Med; 1978; 9(2):183-6. PubMed ID: 276567
[TBL] [Abstract][Full Text] [Related]
3. Hemorrheologic effects of pyrimido-pyrimidine derivatives.
Ambrus JL; Stadler I; Kulaylat M; Koreshi A; Akhtar S
J Med; 1996; 27(1-2):21-32. PubMed ID: 8863175
[TBL] [Abstract][Full Text] [Related]
4. [Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results].
Gastpar H
Laryngol Rhinol Otol (Stuttg); 1983 Dec; 62(12):578-85. PubMed ID: 6369051
[TBL] [Abstract][Full Text] [Related]
5. Studies on the vasoocclusive crisis of sickle cell disease. III. In vitro and in vivo effect of the pyrimido-pyrimidine derivative, RA-233: studies on its mechanism of action.
Ambrus JL; Bannerman RM; Sills RH; Meky N; Sharma S; Stadler S; Gastpar H; Marton J; Melewski DJ
J Med; 1987; 18(3-4):165-98. PubMed ID: 3480932
[TBL] [Abstract][Full Text] [Related]
6. The effect of some pyrimido-pyrimidine derivatives on blood coagulation and platelet aggregation.
Bédi J; Blaskó G; Pálos LA
Arzneimittelforschung; 1979; 29(9):1405-8. PubMed ID: 583250
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic effect of the pyrimido-pyrimidine derivative: RA 233.
Biddle W; Montagna RA; Leong SS; Horoszewicz J; Gastpar H; Ambrus JL
Pathol Biol (Paris); 1984 Jan; 32(1):9-13. PubMed ID: 6701010
[TBL] [Abstract][Full Text] [Related]
8. Study of platelet aggregation in vivo i. Effect of bencyclan.
Ambrus JL; Ambrus CM; Gastpar H; Sapvento PJ; Weber FJ; Thurber LE
J Med; 1976; 7(6):439-47. PubMed ID: 827596
[TBL] [Abstract][Full Text] [Related]
9. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
De La Cruz JP; Moreno A; Mérida F; García Campos J; Sánchez de la Cuesta F
Thromb Res; 1996 Feb; 81(3):327-37. PubMed ID: 8928090
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of compound RA233 and bencyclane on platelet functions--with special reference to the effect on C-AMP metabolism.
Ryo R
Nihon Ketsueki Gakkai Zasshi; 1976 Feb; 39(1):97-108. PubMed ID: 183446
[No Abstract] [Full Text] [Related]
11. Effect of pyrimido-pyrimidine compounds on platelet function.
Cucuianu MP; Nishizawa EE; Mustard JF
J Lab Clin Med; 1971 Jun; 77(6):958-74. PubMed ID: 5559863
[No Abstract] [Full Text] [Related]
12. Platelet aggregation inhibitors in the prevention of metastasis in neoplastic disease: a review of experimental and clinical investigations.
Gastpar H; Ambrus JL; Ambrus CM
J Med; 1981; 12(1):15-33. PubMed ID: 6943264
[No Abstract] [Full Text] [Related]
13. Antiplatelet effect of the pyrimido-pyrimidinic derivative RA-642.
de la Cruz JP; Moron D; Sanchez de la Cuesta F
Thromb Res; 1991 Aug; 63(4):463-8. PubMed ID: 1754999
[No Abstract] [Full Text] [Related]
14. The effect of 2,6-bis(diethanolamino)-4-piperidinopyrimido [5,4-d]-pyrimidine (RA233) on growth, metastases and lung colony formation of B16 melanoma.
Maniglia CA; Tudor G; Gomez J; Sartorelli AC
Cancer Lett; 1982 Sep; 16(3):253-60. PubMed ID: 7151045
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ferrous-induced lipid peroxidation by pyrimido-pyrimidine derivatives in human liver membranes.
de la Cruz JP; Carrasco T; Ortega G; Sanchez de la Cuesta F
Lipids; 1992 Mar; 27(3):192-4. PubMed ID: 1522764
[TBL] [Abstract][Full Text] [Related]
16. The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes.
Bellido I; de la Cruz JP; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1991; 13(6):371-5. PubMed ID: 1881198
[TBL] [Abstract][Full Text] [Related]
17. Effect in vitro on platelet function of two compounds developed from the pyrimido-pyrimidines.
Slater SD; Turpie AG; Douglas AS; McNicol GP
J Clin Pathol; 1972 May; 25(5):427-32. PubMed ID: 5046075
[TBL] [Abstract][Full Text] [Related]
18. The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
de la Cruz JP; Moreno A; Mérida F; García-Campos J; Sánchez de la Cuesta F
Pharmacol Toxicol; 1994 Nov; 75(5):250-4. PubMed ID: 7870694
[TBL] [Abstract][Full Text] [Related]
19. Pyrimido-pyrimidine modulation of EGF growth-promoting activity and p21ras expression in rat mammary adenocarcinoma cells.
Lichtner RB; Gallick GE; Nicolson GL
J Cell Physiol; 1988 Nov; 137(2):285-92. PubMed ID: 3056958
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
